Jubilant Therapeutics Inc. berichtet auf der Jahrestagung 2022 der American Society of Clinical Oncology (ASCO) über die Entwicklung oral verfügbarer und ins Gehirn eindringender niedermolekularer PD-L1-Inhibitoren Deutschland – Deutsch USA – English France – Français
HSS to Offer Free Injury Prevention Program for 50 U.S. High Schools via New “Move Better Play Better” Initiative
Former Jets Champion Willie Colon Hosts NJ Golf Outing, Raising Nearly $350,000 for Lupus Research Alliance
Jury Convicts ISIS ‘Beatle’ for Role in Hostage-Taking Scheme that Resulted in the Deaths of American, British, and Japanese Citizens